Blastic Plasmacytoid Dendritic Cell Neoplasm
📧 Sign up to get email alerts when something new happens for Blastic Plasmacytoid Dendritic Cell Neoplasm.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm [Phase 2]
A Phase 2 clinical trial evaluating venetoclax in combination with SL-401 and chemotherapy for Blastic plasmacytoid dendritic cell neoplasm …
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies [Phase 1, Phase 2]
Phase 1/Phase 2 clinical trial evaluating adaptive dual-target CAR-T cell therapy for relapsed or refractory hematologic malignancies; recru…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry
An update on the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) international registry indicating the study is currently recruiting.
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases [Phase 2]
Phase 2 clinical trial evaluating a cord blood transplant using cyclophosphamide, fludarabine, and total-body irradiation in high-risk hemat…
-
CLINICAL_TRIALS research · 2026-01-13Clinical Trial Update: A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies [Phase 1]
MacroGenics reports a Phase 1 study of MGD024 in relapsed or refractory hematologic malignancies is currently recruiting across multiple dis…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial [EARLY_Phase 1]
This update describes an early-phase dose-escalation trial evaluating CART123 T cells in relapsed or refractory CD123+ hematologic malignanc…
-
CLINICAL_TRIALS research · 2025-11-26Clinical Trial Update: Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients [Phase 2]
Phase II clinical trial evaluating the combination of tagraxofusp and venetoclax in treatment-naive blastic plasmacytoid dendritic cell neop…
-
CLINICAL_TRIALS research · 2025-11-04Clinical Trial Update: SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) [Phase 1]
This is a Phase 1 trial evaluating SL-401 (tagraxofusp) in combination with azacitidine or azacitidine plus venetoclax for acute myeloid leu…
-
CLINICAL_TRIALS research · 2025-09-16Clinical Trial Update: Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm [Phase 1]
This document describes an ongoing Phase 1 clinical trial evaluating a genetically modified T-cell immunotherapy for adults with relapsed/re…
-
CLINICAL_TRIALS research · 2025-05-02Clinical Trial Update: Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies [Phase 1]
Phase 1 study update for Orca-T in recipients undergoing allogeneic transplantation for hematologic malignancies; the trial is currently act…
-
CLINICAL_TRIALS research · 2024-12-16Clinical Trial Update: Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN [Phase 1, Phase 2]
An ongoing Phase 1/2 trial of IMGN632 for untreated and relapsed/refractory Blastic plasmacytoid dendritic cell neoplasm. The study is curre…
-
CLINICAL_TRIALS research · 2024-11-15Clinical Trial Update: Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN [Phase 1]
Phase 1 clinical trial evaluating a CD123-targeted CAR-NK cell therapy for relapsed/refractory acute myeloid leukemia or blastic plasmacytoi…
-
CLINICAL_TRIALS research · 2016-08-09Clinical Trial Update: Descriptive Study of the Efficacy of Treatments for Blastic Dendritic Cell Neoplasm (BPDCN)
This clinical trial update provides a descriptive assessment of the efficacy of treatments used for Blastic Plasmacytoid Dendritic Cell Neop…